An update from Mosaic ImmunoEngineering (CPMV) is now available.
Mosaic ImmunoEngineering Inc., which acquired exclusive rights to develop and commercialize cancer treatments from Case Western Reserve University, is facing a financial crisis. The company defaulted on payments and owes approximately $407,000 in intellectual property fees, leading to the termination of their licensing agreement. With a limited cash position, the company is considering strategic options, including capital infusion, mergers, or business combinations, to avoid winding down operations or dissolving entirely.
See more data about CPMV stock on TipRanks’ Stock Analysis page.
